Inhaled antibiotic developer Insmed has hired Andrea (“Andi”) Holtzman Drucker as its Senior Vice President, General Counsel and Corporate Secretary, which is a newly-created position reporting directly to Insmed President and CEO Timothy Whitten. Drucker commented, “I am excited to be joining the Insmed management team, and look forward to working with the Company as Arikace (liposomal amikacin for inhalation) continues to move forward on its development path through to potential commercialization.”
In December 2010, Insmed acquired Transave and its lead product, Arikace, which is being developed for the treatment of P. aeruginosa lung infections in CF patients and in non-CF patients with bronchiectasis, as well as for nontuberculous mycobacteria (NTM) lung infections. Phase 3 trials have begun for the CF and NTM indications.
Drucker has worked in chemical and biotech companies for most of her career, including stints with FMC, Auxilium Pharmaceuticals and, most recently, PuriCore. “Andi has a distinguished track record of providing strategic legal counsel to growing companies, like Insmed. Her extensive experience with the regulatory and commercial aspects of the pharmaceutical and biotechnology industries, as well as the protection of intellectual property and SEC compliance issues, make her an important addition to our management team,” says Whitten.
Read the Insmed press release.
